PNEUMOVAX® 23 (PPV23)
Catch your eligible patients at any time of the year with PNEUMOVAX® 23 to help prevent pneumococcal disease
PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information [External link]
PNEUMOVAX® 23 is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults1
You can reduce the risk of pneumococcal disease
In the UK, people over the age of 65 are at a higher risk of developing pneumococcal disease vs under
65-year-olds.2 Infected patients face longer hospital stays and an increased risk of mortality —
a difficult prospect for their loved ones2,3
Learn more about the impact of pneumococcal disease
of patients hospitalised for CAP*
were over the age of 654
For every CAP hospitalisation
there is a cost of ~£6,0004
of patients aged 65 only and
31% aged 65 and over were
unvaccinated against pneumococcal
disease in 20205
Catch them at any time of year with PNEUMOVAX®23
Most patients only require a single, 0.5 ml dose of PNEUMOVAX®23 by intramuscular or subcutaneous injection to help protect against 23 Pneumococcal serotypes1
PNEUMOVAX®23 can be administered to eligible patients at your clinic at any time of year, without restriction to winter months
Please consult the SmPC for further information before making any prescribing decisions.
By keeping your eligible patients protected, you can help reduce the burden of pneumococcal disease on healthcare systems, including the 40,000 annual hospitalisations6
Find out how administering PNEUMOVAX® 23 at any time of year can help protect patients and hospitals
Check who is eligible for PNEUMOVAX® 23 on the National Immunisation Programme
Safety Information
Stock ordering and status
Training and Resources
*CAP; community-acquired pneumonia
References
- PNEUMOVAX 23 Summary of Product Characteristics.
- Grant LR, et al. Expert Rev Vaccines. 2021;20(6):691-705.
- NHS. RightCare Community-acquired Pneumonia Toolkit. Available at: https://www.england.nhs.uk/rightcare/wp-content/uploads/sites/40/2022/09/RightCare-Pneumonia-toolkit.pdf. [Date accessed: September 2024].
- Campling J, et al. J Med Econ. 2022;25(1):912–918.
- Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2020 to March 2021. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1035189/hpr1921-ppv-vc.pdf. [Accessed: September 2024].
- Oxford Vaccine Group. Vaccine Knowledge Project. Pneumococcal disease. Available at: https://vk.ovg.ox.ac.uk/pneumococcal-disease#Key-disease-facts [Accessed: September 2024].
Supporting documentation
PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website